| 2023-11-09 |
复牌提示：
2023-11-08 19:50:09 停牌，复牌日期 2023-11-10 00:00:01
|
| 2023-11-06 |
详情>>
股本变动：
变动后总股本48769.62万股
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.49美元,归母净利润-2.38亿美元,同比去年增长-62.1%
|
| 2023-09-29 |
股东大会：
将于2023-11-08召开股东大会
会议内容 ▼▲
- 1.To approve the issuance of shares of Revolution Medicines common stock (including securities convertible into or exercisable for shares of Revolution Medicines common stock) to certain equityholders of EQRx, Inc., which is referred to as EQRx, pursuant to the Agreement and Plan of Merger, dated as of July 31, 2023 (as it may be amended from time to time), by and among Revolution Medicines, Equinox Merger Sub I, Inc., a wholly owned subsidiary of Revolution Medicines, Equinox Merger Sub II LLC, a wholly owned subsidiary of Revolution Medicines, and EQRx, which is referred to as the merger agreement, a copy of which is included as Annex A to the accompanying joint proxy statement/prospectus, which proposal is referred to as the Revolution Medicines share issuance proposal;
2.To approve the adjournment of the Revolution Medicines special meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Revolution Medicines special meeting to approve the Revolution Medicines share issuance proposal, which proposal is referred to as the Revolution Medicines adjournment proposal.
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.32美元,归母净利润-1.56亿美元,同比去年增长-151.55%
|
| 2023-05-08 |
详情>>
业绩披露：
2023年一季报每股收益-0.17美元,归母净利润-8255.1万美元,同比去年增长-498.3%
|
| 2023-05-08 |
财报披露：
美东时间 2023-05-08 盘后发布财报
|
| 2023-02-23 |
详情>>
业绩披露：
2022年年报每股收益-0.36美元,归母净利润-1.69亿美元,同比去年增长-69.07%
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.31美元,归母净利润-1.47亿美元,同比去年增长-480.77%
|
| 2022-08-12 |
股东大会：
将于2022-09-30召开股东大会
会议内容 ▼▲
- 1.To elect the to our board of directors (the Board) its three nominees for director named herein to hold office until the 2025 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier resignation, death or removal.
2.To ratify the selection by the Audit Committee of the Board of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.
3.To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.
|
| 2022-08-11 |
详情>>
业绩披露：
2022年中报每股收益-0.13美元,归母净利润-6182万美元,同比去年增长-94.16%
|
| 2022-05-13 |
详情>>
业绩披露：
2022年一季报每股收益0.04美元,归母净利润2072.60万美元,同比去年增长57012.98%
|
| 2022-03-23 |
详情>>
业绩披露：
2021年年报每股收益-0.31美元,归母净利润-1亿美元,同比去年增长59.99%
|
| 2021-12-17 |
详情>>
内部人交易：
Rubin Jami等共交易9笔
|